- Companies
- Tesis Labs LLC
Tesis Labs LLC Valuation, Funding & Investors
Tesis Labs LLC is valued at $520M as of September 2021.
Last Tesis Labs LLC valuation
$520M
Undisclosed stage · Sep 2021
Last Tesis Labs LLC funding round
$16M
Undisclosed stage · Jan 2022
Cumulative funding Tesis Labs LLC raised
$40M
across 4 funding rounds
Tesis Labs LLC Overview
About Tesis Labs LLC
Tesis Labs LLC is a Montevideo, Uruguay-headquartered developer of healthcare management software deployed in clinics across Latin America. Its platform streamlines electronic health records, telemedicine consultations, and billing for over 100 facilities. Tesis Labs integrates with national health systems for real-time patient data exchange.
Founded
2019
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Subscription
Valuation
$520M (Sep 2021)
Sectors
Tesis Labs LLC Valuation
Tesis Labs LLC is currently valued at $520M, based on its undisclosed-stage round in September 2021.
Tesis Labs LLC's valuation has moved from $520M at its seed round in July 2020 to $520M in September 2021, across 2 priced rounds.
Tesis Labs LLC valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Sep 2021 | Undisclosed stage | $520M |
| Jul 2020 | Seed | $520M |
Tesis Labs LLC Funding History
Tesis Labs LLC has raised a total of $40M across 4 funding rounds.
Tesis Labs LLC's first fundraising round was a $1M seed round in December 2019. The most recent completed round was a $16M undisclosed-stage round in January 2022.
Tesis Labs LLC funding rounds
| Date | Stage | Raised | Valuation | Deal Summary |
|---|---|---|---|---|
| Jan 2022 | Undisclosed stage | $16M | - | - |
| Sep 2021 | Undisclosed stage | $20M | $520M | Tesis Labs LLC, a Phoenix-based biotech startup founded in early 2020, specializes in targeted genetic sequencing and precision medicine, providing healthcare providers with genetic testing tools to create personalized care plans for chronic diseases like heart disease, lung disease, and cancer. The company focuses on next-generation sequencing (NGS) testing with proprietary molecular panels and supports clinical research initiatives for preventative medicine and population health. On approximately September 30, 2021, Tesis Labs raised $20 million in its first external growth equity financing round, led by Xcellerant 1 TLC, LLC, an investment group headed by Arizona health entrepreneur John Shufeldt, MD. This Series A round achieved a post-money valuation of $520 million. Prior to this, the company had bootstrapped approximately $15 million from internal sources. The funding enables Tesis Labs to expand testing capacity significantly, including growing its labs in Denver, Lafayette (Colorado), and Houston, and opening a new facility in Scottsdale, Arizona, in December 2021, which alone would more than double current capacity. Plans also include building additional facilities nationwide to meet rising customer demand from clinical joint venture partners. Tesis Labs' in-house R&D team develops advanced diagnostic panels to assist partners in clinical trials, validating therapies for early non-symptomatic recognition and streamlining go-to-market timelines. The company positions itself at the forefront of precision medicine through genetic integration across generations. |
| Jul 2020 | Seed | $3M | $520M | Tesis Labs LLC is a Phoenix, AZ-based company specializing in targeted genetic sequencing, offering healthcare providers and physicians access to genetic testing and precision medicine for personalized care plans targeting chronic diseases like heart disease, lung disease, and cancer. The company provides unique diagnostic panels using next-generation sequencing (NGS) to support clinical trials, validate therapies, and streamline workflows for partners. Tesis Labs raised $20 million in growth equity financing in October 2021 at a post-money valuation of $520 million, led by Xcellerant 1 TLC, LLC. This was the first external financing since operations began in early 2020, following approximately $15 million raised prior. Funds supported expansion of clinical capacity, production, and proprietary product validation. Later rounds included a $20 million filing in October 2021 and $16 million in January 2022. |
| Dec 2019 | Seed | $1M | - | - |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialTesis Labs LLC Competitors
Tesis Labs LLC competitors include listed companies like Chularat Hospital, Garofalo Health Care, Sikarin and Strata Critical Medical, and private ones like Neuberg Diagnostics and Harbor Health.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $251M | $52M | $525M | 2.0x | ||
| Publicly listed | $559M | $83M | $548M | 1.4x | ||
| Publicly listed | $181M | $47M | $479M | - | ||
| Publicly listed | $197M | ($16M) | $476M | 1.7x | ||
| Private | $107M | - | $642M | 6.0x | ||
| Private | - | - | $650M | - |
Tesis Labs LLC Public Comps
Tesis Labs LLC is still privately-owned, but its public comps include Chularat Hospital, Garofalo Health Care, Sikarin, Strata Critical Medical, Hermina Hospitals, M1 Kliniken, Integral Diagnostics, Community Health Systems, Al-Maidan Dental Clinic and Auna.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $251M | $52M | 2.1x | 2.0x | 9.8x | 9.5x | |||
| $559M | $83M | 1.5x | 1.4x | 9.8x | 8.6x | |||
| $181M | $47M | 2.5x | - | 9.7x | - | |||
| $197M | ($16M) | 2.3x | 1.7x | (28.4x) | 16.4x | |||
| $402M | $104M | 2.1x | 1.9x | 8.1x | 7.5x | |||
| $420M | $46M | 0.9x | 1.7x | 8.6x | 9.8x | |||
| $561M | $99M | 1.8x | 1.8x | 10.2x | 8.4x | |||
| $12B | $2B | 0.9x | 0.9x | 5.5x | 8.0x | |||
This data is available for Pro users. Sign up to see all Tesis Labs LLC competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Tesis Labs LLC
| When was Tesis Labs LLC founded? | Tesis Labs LLC was founded in 2019. |
| Where is Tesis Labs LLC headquartered? | Tesis Labs LLC is headquartered in Phoenix, AZ, United States. |
| Is Tesis Labs LLC publicly listed? | No, Tesis Labs LLC is a private company. |
| What is Tesis Labs LLC's valuation? | Tesis Labs LLC was last valued at $520M in its undisclosed-stage round in September 2021. |
| How much funding has Tesis Labs LLC raised? | Tesis Labs LLC has raised $40M across 4 funding rounds. |
| What was Tesis Labs LLC's last funding round? | Tesis Labs LLC's last funding round was a $16M undisclosed-stage round in January 2022. |
| Which companies are comparable to Tesis Labs LLC? | Companies comparable to Tesis Labs LLC include Chularat Hospital, Garofalo Health Care, Sikarin, Strata Critical Medical, Neuberg Diagnostics and Harbor Health. |
See companies similar to Tesis Labs LLC
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




